Regulus Therapeutics(RGLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGLS Regulus Therapeutics

Halted 12-11 19:57:24 EST

8.16

+0.00

0.00%

High8.16	Low8.16	Vol0.00
Open8.16	D1 Closing8.16	Amplitude0.00%
Mkt Cap564.95M	Tradable Cap431.98M	Total Shares69.23M
T/O75.91M	T/O Rate0.00%	Tradable Shares52.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGLS","market":"US","secType":"STK","nameCN":"Regulus Therapeutics","latestPrice":8.16,"timestamp":1750795200000,"preClose":8.16,"halted":3,"volume":0,"delay":0,"floatShares":52938400,"shares":69234089,"eps":-0.7233,"marketStatus":"Halted","change":0,"latestTime":"12-11 19:57:24 EST","open":8.16,"high":8.16,"low":8.16,"amount":75911220.43810101,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.7233,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1349323200000,"exchange":"NASDAQ","adjPreClose":8.16,"volumeRatio":0},"requestUrl":"/m/hq/s/RGLS/tweets","defaultTab":"tweets","newsList":[{"id":"2546243599","title":"BRIEF-Novartis Completes Acquisition Of Regulus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2546243599","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546243599?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:15","pubTimestamp":1750857310,"startTime":"0","endTime":"0","summary":"BRIEF-Novartis Completes Acquisition Of Regulus TherapeuticsJune 25 (Reuters) - Novartis AG NOVN.S:NOVARTIS COMPLETES ACQUISITION OF REGULUS THERAPEUTICSNOVARTIS AG - COMPLETES ACQUISITION OF REGULUS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUA2ZVXW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGLS"],"gpt_icon":0},{"id":"2546324800","title":"Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2546324800","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546324800?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:13","pubTimestamp":1750857207,"startTime":"0","endTime":"0","summary":"Novartis AG has successfully completed its acquisition of Regulus Therapeutics Inc., making Regulus an indirect wholly owned subsidiary of Novartis. This acquisition marks a step forward in Novartis' efforts to advance clinical development for a potential first-in-class medicine targeting autosomal dominant polycystic kidney disease , a leading genetic cause of renal failure globally. The merger was finalized through Novartis' subsidiary, Redwood Merger Sub Inc., and involved a tender offer where existing shareholders received cash and contingent value rights. This strategic move enhances Novartis' renal disease pipeline, integrating the expertise of Regulus' team and building on promising Phase 1b trial results for farabursen, an investigational treatment aimed at reducing cyst growth and disease progression in ADPKD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL6FCkjc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","RGLS","NDAQ","BK4139","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2546715264","title":"Novartis' Tender Offer for Regulus Therapeutics Expires with 74.49% Shareholder Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=2546715264","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546715264?lang=en_us&edition=fundamental","pubTime":"2025-06-25 13:00","pubTimestamp":1750827617,"startTime":"0","endTime":"0","summary":"Novartis AG has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc. through its indirect subsidiary, Redwood Merger Sub Inc. The offer aimed to purchase all outstanding shares of Regulus at $7.00 per share in cash, plus one contingent value right per share for a potential additional $7.00 contingent on meeting a regulatory milestone. As of the expiration of the offer on June 24, 2025, approximately 74.49% of Regulus's shares were tendered. The transaction is expected to close on June 25, 2025, following the acceptance of the tendered shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire  on June 25, 2025, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL2vzdzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","RGLS","NDAQ","BK4585","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU2095319765.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2545469013","title":"Novartis AG Announces Expiration of Antitrust Waiting Period for Regulus Therapeutics Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2545469013","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545469013?lang=en_us&edition=fundamental","pubTime":"2025-06-23 13:00","pubTimestamp":1750654822,"startTime":"0","endTime":"0","summary":"Novartis AG has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, related to its tender offer to acquire all outstanding shares of Regulus Therapeutics Inc. The expiration of this waiting period, which occurred at 11:59 p.m. on June 20, 2025, is a crucial step towards the completion of the transaction. Under the agreement, Novartis will offer $7.00 in cash per share of Regulus, along with a contingent value right for a potential additional payment of $7.00 in cash, contingent on the achievement of a regulatory milestone. The tender offer is set to expire one minute past 11:59 p.m. on June 24, 2025, unless extended or terminated earlier.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL9ph4Kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","BK4139","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","RGLS","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2541091596","title":"Preston Klassen, President & Head of R&D, Reports Acquisition of Common Shares in Regulus Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541091596","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541091596?lang=en_us&edition=fundamental","pubTime":"2025-06-05 05:00","pubTimestamp":1749070851,"startTime":"0","endTime":"0","summary":"Preston Klassen, President & Head of R&D at Regulus Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regulus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL3drK5t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Preston Klassen, President & Head of R&D, Reports Acquisition of Common Shares in Regulus Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS","BK4139"],"gpt_icon":0},{"id":"2538465077","title":"Novartis Ag  - Novartis Announces Commencement of Tender Offer to Acquire Regulus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465077?lang=en_us&edition=fundamental","pubTime":"2025-05-27 20:05","pubTimestamp":1748347503,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ10M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RGLS"],"gpt_icon":0},{"id":"2538946518","title":"Novartis Launches Tender Offer to Acquire Regulus Therapeutics for $7.00 Per Share Plus Contingent Value Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2538946518","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538946518?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:56","pubTimestamp":1748346969,"startTime":"0","endTime":"0","summary":"Novartis AG has announced the commencement of a tender offer through its indirect wholly owned subsidiary, Redwood Merger Sub Inc., to acquire all outstanding shares of Regulus Therapeutics Inc. at $7.00 per share in cash, plus a contingent value right for an additional cash payment of $7.00 upon achieving a regulatory milestone. The offer, set in accordance with an Agreement and Plan of Merger dated April 29, 2025, will expire at one minute past 11:59 p.m. on June 24, 2025, unless extended or terminated earlier. Novartis has filed a tender offer statement with the SEC detailing the terms and conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL8F3MX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","BK4139","RGLS","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2538746590","title":"Novartis Ag - Offer Includes $7.00 Cash per Share Plus Contingent Value Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2538746590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538746590?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:55","pubTimestamp":1748346957,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA86VYFJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGLS","BK4139"],"gpt_icon":0},{"id":"2538465909","title":"Novartis Ag - Offer Subject to Customary Conditions Including Hart-Scott-Rodino Act","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465909?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:55","pubTimestamp":1748346957,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA86VYFJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RGLS"],"gpt_icon":0},{"id":"2538465906","title":"Novartis Ag - Offer to Expire on June 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2538465906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538465906?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:55","pubTimestamp":1748346957,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nTUA86VYFJ:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGLS","BK4139"],"gpt_icon":0},{"id":"2537626656","title":"Regulus Resources Inc. Unveils Corporate Presentation Highlighting AntaKori Copper-Gold Project and Long-Term Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537626656","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537626656?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:29","pubTimestamp":1747776557,"startTime":"0","endTime":"0","summary":"Regulus Resources Inc. has released a corporate presentation detailing its operations and strategic initiatives. The presentation highlights the company's focus on the AntaKori Copper-Gold Project, described as a world-class brownfield opportunity. It outlines Regulus's long-term strategy which involves acquiring mineral resources with overlooked potential, expanding resource value through exploration and project de-risking, and eventually monetizing by selling to major mining companies. The management team, noted for its successful track record, is aligned with shareholders and experienced in working within Peru. The presentation also emphasizes the importance of copper projects for the green energy transition and notes the company's active involvement in local community projects and collaborations with neighboring mines. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDLbsyRW9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGLS"],"gpt_icon":0},{"id":"2534280162","title":"Regulus Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534280162","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534280162?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:58","pubTimestamp":1746737938,"startTime":"0","endTime":"0","summary":"Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 48.28 percent increase over losses of $(0.29) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45302784/regulus-therapeutics-q1-eps-0-15-beats-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS"],"gpt_icon":0},{"id":"2534416256","title":"Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534416256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534416256?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:52","pubTimestamp":1746737577,"startTime":"0","endTime":"0","summary":"Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRegulus Therapeutics Inc RGLS.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nL8N3RG3HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS"],"gpt_icon":0},{"id":"2534661961","title":"Regulus Therapeutics Reports Increased R&D and G&A Expenses in Q1 2025; Cash Runway Extends to Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2534661961","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534661961?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:06","pubTimestamp":1746734776,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regulus Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL6pqP55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS","BK4139"],"gpt_icon":0},{"id":"2534989166","title":"Regulus Therapeutics Q1 Basic EPS USD -0.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2534989166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534989166?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:05","pubTimestamp":1746734710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nPLX648D05:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RGLS"],"gpt_icon":0},{"id":"2533550564","title":"Regulus Therapeutics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533550564","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533550564?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:04","pubTimestamp":1746475445,"startTime":"0","endTime":"0","summary":"Regulus Therapeutics Inc  expected to post a loss of24cents a share - Earnings Preview Regulus Therapeutics Inc RGLS.OQ RGLS.O is expected to show no change in quarterly revenue when it reports  resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD25B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS"],"gpt_icon":0},{"id":"2532001467","title":"Regulus Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2532001467","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532001467?lang=en_us&edition=fundamental","pubTime":"2025-05-01 23:07","pubTimestamp":1746112020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2025 11:07 ET (15:07 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGLS"],"gpt_icon":0},{"id":"2532507507","title":"Oppenheimer Downgrades Regulus Therapeutics to Market Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2532507507","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532507507?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:35","pubTimestamp":1746099355,"startTime":"0","endTime":"0","summary":"Regulus Therapeutics (RGLS) has an average rating of hold and mean price target of $8.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGLS","OPY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regulusrx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0062},{"period":"1year","weight":3.9756},{"period":"ytd","weight":4.1646}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":-0.043674},{"month":2,"riseRate":0.384615,"avgChangeRate":0.02347},{"month":3,"riseRate":0.538462,"avgChangeRate":0.105895},{"month":4,"riseRate":0.307692,"avgChangeRate":0.22053},{"month":5,"riseRate":0.538462,"avgChangeRate":0.07742},{"month":6,"riseRate":0.384615,"avgChangeRate":-0.107927},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.130856},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.042258},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.004778},{"month":10,"riseRate":0.166667,"avgChangeRate":0.026008},{"month":11,"riseRate":0.461538,"avgChangeRate":0.057414},{"month":12,"riseRate":0.384615,"avgChangeRate":0.049982}],"exchange":"NASDAQ","name":"Regulus Therapeutics","nameEN":"Regulus Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regulus Therapeutics(RGLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regulus Therapeutics(RGLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regulus Therapeutics,RGLS,Regulus Therapeutics股票,Regulus Therapeutics股票老虎,Regulus Therapeutics股票老虎国际,Regulus Therapeutics行情,Regulus Therapeutics股票行情,Regulus Therapeutics股价,Regulus Therapeutics股市,Regulus Therapeutics股票价格,Regulus Therapeutics股票交易,Regulus Therapeutics股票购买,Regulus Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regulus Therapeutics(RGLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regulus Therapeutics(RGLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction